
|Articles|June 20, 2019
Thrive or Die in the Omnichannel Era
Author(s)BioPharm Communications
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
340B Under Pressure: Inside Pharma's Push for Greater Clarity
3
The Agentic AI Revolution in Biopharma
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5




